NeoGenomics, Inc. NEO
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +40.22%
- 1 year
- +68.78%
- Open
- 17.66
- Prev close
- 17.38
- Mkt cap
- 2.13B
- Vol
- 1.71M
- Avg vol
- 2.03M
- EPS
- -0.24
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 16.29
- High
- 17.66
- Forward P/E
- 52.42
- Beta
- 1.83
- Short ratio
- 5.78
- Inst. own
- 115.09%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 16, 2027
- 50-d avg
- 17.68
- 200-d avg
- 12.78
- 1y target
- 23.78
News
10 hours ago globenewswire.com
NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
CALABASAS, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for…
4 days ago prnewswire.com
NEO Battery Reports Fiscal Year 2027 Second Quarter Results
TORONTO, Oct. 29, 2026 /PRNewswire/ -- NEO Battery Materials Ltd. ("NEO" or the "Company") (TSXV: NBM) (OTC: NBMFF), a low-cost, silicon-enhanced battery manufacturer enabling high-performance…
-
4 days ago benzinga.com
TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $23
TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $19 to $23.
4 days ago marketbeat.com
What NeoGenomics (NEO) Said on Its Q3 Earnings Call
NeoGenomics NASDAQ: NEO reported third-quarter revenue growth of 11% year over year, led by continued expansion in next-generation sequencing, or NGS, testing, while raising its full-year revenue and…
5 days ago benzinga.com
NeoGenomics Q3 2026 Earnings Call Transcript
NeoGenomics (NASDAQ:NEO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…
-
5 days ago benzinga.com
NeoGenomics Raises FY2026 Sales Guidance from $802.000M-$806.000M to $807.000M-$809.000M vs $805.827M Est
NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $802.000 million-$806.000 million to $807.000 million-$809.000 million vs $805.827 million estimate.
-
5 days ago benzinga.com
NeoGenomics Q3 Adj. EPS $0.07 Beats $0.05 Estimate, Sales $209.254M Beat $207.328M Estimate
NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.05 by 40 percent. This is a 133.33 percent increase over earnings of $0.03 per…
5 days ago businesswire.com
NeoGenomics Reports Third Quarter 2026 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its third-quarter results for the period ended September 30, 2026.
2 weeks ago newsfilecorp.com
NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
Pediatric Case, Abu Dhabi Expansion and Board Appointment Highlight a Broader Development Strategy Houston, Texas--(Newsfile Corp. - October 16, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is…
2 weeks ago globenewswire.com
NeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone
DENVER, Oct. 16, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ: NTHI) delivered a deeply human clinical update that brings its investigational brain-cancer…
2 weeks ago globenewswire.com
NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi
CALABASAS, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for…
2 weeks ago businesswire.com
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics expanded its partnership with Indica Labs to scale AI-powered digital pathology and support more timely, consistent diagnostic insights.
2 weeks ago gurufocus.com
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its thi
2 weeks ago businesswire.com
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026.
3 weeks ago benzinga.com
What's Going On With NeoGenomics Stock Tuesday?
Precision medicine and oncology diagnostics provider NeoGenomics Inc. (NASDAQ:NEO) on Monday announced an executive succession plan and preliminary third-quarter financial results for the period…
3 weeks ago benzinga.com
What's Going On With NeoGenomics Stock Tuesday?
NeoGenomics stock falls after leadership shuffle and Q3 preliminary results. Analysts weigh in on growth and valuation.
3 weeks ago defenseworld.net
NeoGenomics (NASDAQ:NEO) Hits New 12-Month High After Analyst Upgrade
NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report)'s stock price reached a new 52-week high during trading on Tuesday after Needham and Company LLC raised their price target on the stock from $19.00…
3 weeks ago benzinga.com
General Motors To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts raised targets for PTC, Cloudflare, PENN, Microsoft and others, while downgrading PTC and upgrading PENN and Abbott.
-
3 weeks ago benzinga.com
StoneX Maintains Buy on NeoGenomics, Raises Price Target to $20
StoneX analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $16 to $20.
3 weeks ago benzinga.com
This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded Boyd Gaming, NeoGenomics, PENN Entertainment, XP and Rezolute, raising targets for several names.
-
3 weeks ago benzinga.com
Needham Maintains Buy on NeoGenomics, Raises Price Target to $22
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $19 to $22.
-
4 weeks ago benzinga.com
NeoGenomics Appoints President, COO Warren Stone As CEO, Effective Jan, 4 Next Year, Succeeding Tony Zook; Zook Appointed Executive Chair, Succeeding Lynn Tetrault
NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that as part of a planned…
4 weeks ago businesswire.com
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of directors succession plan.
1 month ago globenewswire.com
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
CALABASAS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for…
1 month ago defenseworld.net
Omada Health (NASDAQ:OMDA) and NeoGenomics (NASDAQ:NEO) Head-To-Head Contrast
NeoGenomics (NASDAQ: NEO - Get Free Report) and Omada Health (NASDAQ: OMDA - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies…
1 month ago defenseworld.net
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
NeoGenomics (NASDAQ: NEO) executives outlined the company's strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual…
1 month ago marketbeat.com
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
NeoGenomics NASDAQ: NEO executives outlined the company's strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease…
1 month ago globenewswire.com
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results
CALABASAS, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing…
1 month ago fool.com
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
1 month ago globenewswire.com
NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data
DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is entering a potentially important new phase with fresh institutional capital, encouraging…
-
2 months ago benzinga.com
NeoGenomics’ RaDaR ST Molecular Residual Disease Assay Receives Expanded Coverage From CMS’ MolDX To Include Immunotherapy Monitoring For Patients With Late-Stage Solid Tumors
New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuumNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology…
2 months ago benzinga.com
Greenland Mines Outlines $2B Valuation for Sarfartoq Project
Greenland Mines released an Initial Assessment for its Sarfartoq project, projecting a pre-tax net present value up to $2.05 billion.
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's regular session. The market value of their outstanding shares is at $1.4 million. SciSparc (NASDAQ:SPRC)…
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday's pre-market session. The company's market cap stands at $1.4 million. OneMedNet (NASDAQ:ONMD) shares…
-
3 months ago benzinga.com
Needham Maintains Buy on NeoGenomics, Raises Price Target to $19
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $15 to $19.
-
3 months ago benzinga.com
NeoGenomics Raises FY2026 Sales Guidance from $797.000M-$803.000M to $802.000M-$806.000M vs $800.433M Est
NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $797.000 million-$803.000 million to $802.000 million-$806.000 million vs $800.433 million estimate.
-
3 months ago benzinga.com
NeoGenomics Q2 Adj. EPS $0.05 Beats $0.03 Estimate, Sales $202.000M Beat $196.997M Estimate
NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66.67 percent. This is a 66.67 percent increase over earnings of $0.03…
-
3 months ago benzinga.com
Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $16
Benchmark analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $11 to $16.
-
3 months ago benzinga.com
NeoGenomics Reveals Settlement Of Voluntary Disclosure To OIG-HHS; Co To Pay $9,813,260 Plus Interest At A Rate Of 4.250% Per Annum From January 16, 2026 To Resolve The Matter
NeoGenomics, Inc. (the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the…
-
3 months ago benzinga.com
NeoGenomics Launches PTEN IHC CDx, Immunohistochemistry Companion Diagnostic Test Approved By FDA For Patients With Prostate Adenocarcinoma
Available within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx identifies patients who may be eligible for TRUQAP®NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of…
-
4 months ago benzinga.com
NeoGenomics Prices Offering Of $275M Of 0.75% Convertible Senior Notes Due 2032
In addition, NeoGenomics granted the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the notes are first…
-
4 months ago benzinga.com
NeoGenomics Commences A Private Offering Of $275M Aggregate Principal Amount Of Convertible Senior Notes Due 2032
solutions that enable precision medicine, announced today that it has commenced a private offering of $275 million aggregate principal amount of convertible senior notes due 2032 (the "notes") to…
-
5 months ago benzinga.com
NeoGenomics To Showcase Eight Scientific Abstracts, Highlighting Advances In MRD, Precision Oncology, And Real-World Evidence Across Solid Tumors And Hematologic Malignancies, At 2026 ASCO Annual Meeting
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it will showcase eight scientific abstracts at the 2026 American…
-
6 months ago benzinga.com
Benchmark Upgrades NeoGenomics to Buy, Announces $11 Price Target
Benchmark analyst Bruce Jackson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and announces $11 price target.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
6 months ago benzinga.com
Earnings Scheduled For April 28, 2026
Earnings Scheduled For April 28, 2026
-
7 months ago benzinga.com
Earnings Scheduled For March 19, 2026
Earnings Scheduled For March 19, 2026
-
8 months ago benzinga.com
Earnings Scheduled For February 17, 2026
Earnings Scheduled For February 17, 2026
10 months ago benzinga.com
Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session